Metastatic BRAF-mutant melanoma
Cross-source consensus on Metastatic BRAF-mutant melanoma from 1 sources and 3 claims.
1 sources · 3 claims
How it works
Where it comes from
Highlighted claims
- Approximately 40–50% of metastatic melanomas have activating BRAF mutations. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- The BRAF V600E mutation constitutively activates BRAF kinase and MAPK/ERK signalling, promoting tumour progression. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- Melanoma is especially susceptible to immune checkpoint inhibition because it is highly immunogenic. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials